Log in

NASDAQ:VSTM - Verastem Stock Price, Forecast & News

$1.32
+0.07 (+5.60 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$1.25
Now: $1.32
$1.35
50-Day Range
$0.85
MA: $1.15
$1.42
52-Week Range
$0.83
Now: $1.32
$4.69
Volume2.19 million shs
Average Volume2.01 million shs
Market Capitalization$98.14 million
P/E RatioN/A
Dividend YieldN/A
Beta2.98
Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.72 million
Book Value$1.68 per share

Profitability

Net Income$-72,430,000.00
Net Margins-809.25%

Miscellaneous

Employees169
Market Cap$98.14 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.


Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) issued its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.14. The biopharmaceutical company had revenue of $15.51 million for the quarter. Verastem had a negative return on equity of 160.88% and a negative net margin of 809.25%. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

6 equities research analysts have issued 1-year price objectives for Verastem's shares. Their forecasts range from $2.50 to $9.00. On average, they expect Verastem's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 335.6% from the stock's current price. View Analyst Price Targets for Verastem.

What is the consensus analysts' recommendation for Verastem?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:
  • 1. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (7/13/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of VSTM and lower our 12-month price target to $2.50 per share, down from $10.00. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying an 8x multiple to our 2025 sales estimate discounted at 12%; and (2) price-earnings multiple analysis applying an 18x multiple to our 2025 estimated earnings discounted at 12%. (1) commercial; (2) clinical; (3) financial; (4) regulatory; and (5) intellectual property." (5/10/2019)

Has Verastem been receiving favorable news coverage?

News articles about VSTM stock have trended negative recently, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Verastem earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Verastem.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 55)
  • Mr. Robert E. Gagnon, Chief Financial Officer (Age 45)
  • Mr. Joseph M. Lobacki, Exec. VP & Chief Commercial Officer (Age 61)
  • Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 65)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board

Who are Verastem's major shareholders?

Verastem's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Stifel Financial Corp (0.41%), State Street Corp (0.18%), Millennium Management LLC (0.07%) and SeaCrest Wealth Management LLC (0.03%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Which institutional investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Stifel Financial Corp, State Street Corp and SeaCrest Wealth Management LLC. View Insider Buying and Selling for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $1.32.

How big of a company is Verastem?

Verastem has a market capitalization of $98.14 million and generates $26.72 million in revenue each year. The biopharmaceutical company earns $-72,430,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Verastem employs 169 workers across the globe.View Additional Information About Verastem.

What is Verastem's official website?

The official website for Verastem is http://www.verastem.com/.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]


MarketBeat Community Rating for Verastem (NASDAQ VSTM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  469 (Vote Outperform)
Underperform Votes:  414 (Vote Underperform)
Total Votes:  883
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel